Orthocell has today released its Quarterly Report for the period ended 31 December 2025 – a quarter marked by continued revenue growth and accelerating U.S. commercialisation.
Key highlights for the quarter include:
- Seventh consecutive quarter of record revenue of $3.2 million, driven by Remplir’s growing penetration across existing markets and initial U.S. sales.
- Strong financial position, with cash reserves of $49.4 million as at 31 December 2025, following a successful $30 million institutional capital raise.
- US commercialisation ahead of expectations, with distributor coverage now spanning 25+ states and reaching 40% of the U.S. population, and the first 100 US sales achieved.
- Progress across new markets, including Canada and Hong Kong, with first Canadian sales expected in CY26.
- Regulatory application submitted for the EU and UK nerve repair markets, with approval expected in 3Q CY26.
- Expanded complementary product portfolio, otherwise global distribution rights to PearlBone™ bone regeneration technology.
- Momentum continues for prostate nerve-sparing surgery opportunity with ~100 Remplir procedures completed.